{
    "nctId": "NCT06227728",
    "briefTitle": "Analysis of PD-L1, TMB, MSI and ctDNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.",
    "officialTitle": "Analysis of PD-L1, TMB, MSI and Circulating Tumor DNA Dynamics to Predict and Monitor Response to Immunotherapy in Metastatic Cancer.",
    "overallStatus": "RECRUITING",
    "conditions": "Non Small Cell Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer, Advanced Cancer, Immune Checkpoint Inhibitor",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "To investigate the relationship between ctDNA dynamics and clinical response to immune checkpoint inhibitors (ICIs) (assessed by RECIST 1.1).",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 18 years and older, both genders.\n* Patients are diagnosed with stage IV cancer (lung, colorectal, breast, liver, gastric...) and indicated for ICI (first or second line). Concurrent chemotherapy with ICI is allowed.\n* FFPE/FNA sample is available.\n* Compliant with treatment protocol.\n* Patients consented to participate in the study.\n\nExclusion Criteria:\n\n* Patients already started ICI before enrollment.\n* Consolidation ICI (eg. Durvalumab).\n* Patients already started chemotherapy before enrollment.\n* Medical or psychiatric conditions or occupational responsibilities that may preclude compliance with the protocol.\n* Patients did not agree to participate in the studies.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}